HopeStage
Back to all studies
CompletedNCT01279213

Paliperidone Added to Clozapine for Resistant Schizophrenia

About this titleRead the official source — NCT01279213
Medication studyAges 20–50Argentina
The study in practice

Understand this study

Who was this study for?

Listed age limits: 20 years to 50 years.

Listed locations
RosarioSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJanuary 2009
Recruitment status
Completed
Enrollment listed in the registry
70
Sponsor
Universidad Nacional de Rosario
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Argentina
Age range
From 20 Years to 50 Years
Official registry ID
NCT01279213
Official title
Show the full official title

Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Rosario

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Universidad Nacional de Rosario.

Did this study involve medication?

Yes. The study involved medication, including paliperidone clozapine.

Who was this study for?

Listed age limits: 20 years to 50 years.

Want to explore more studies?

Explore studies